AGLE - Aeglea BioTherapeutics, Inc.
| Previous Close | 6.77 |
| Open | 6.79 |
| Bid | 6.50 x 900 |
| Ask | 6.97 x 1400 |
| Day's Range | 6.61 - 6.87 |
| 52 Week Range | 6.31 - 12.00 |
| Volume | 77,596 |
| Avg. Volume | 181,806 |
| Market Cap | 196.745M |
| Beta (3Y Monthly) | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.23 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.20 |
- TheStreet.com•2 days ago
These 3 Biotech Stocks Are Attracting Insider Buying
Volatility continues to pick up as trade tensions between the U.S. and China continue to escalate with no current end in sight. Add in EU elections and the coming departure of the prime minister in the U.
- GuruFocus.com•3 days ago
Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $180,028 of Shares
President & CEO of Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Anthony G. Quinn bought 26,592 shares of AGLE on 05/22/2019 at an average price of $6.77 a share.
- Associated Press•19 days ago
Aeglea: 1Q Earnings Snapshot
On a per-share basis, the Austin, Texas-based company said it had a loss of 59 cents. Aeglea shares have dropped 6.5% since the beginning of the year. The stock has declined 28% in the last 12 months. ...
- GlobeNewswire•19 days ago
Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights
Statistically Significant Reductions in Plasma Arginine with Accompanying Clinical Improvements with Pegzilarginase in Phase 1/2 Reaffirm Pivotal Trial Design Gross Proceeds of.
- Simply Wall St.•29 days ago
Have Insiders Been Selling Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have been known to precede tough periods for a business. So we'll take a look...
- Zacks•2 months ago
Aeglea (AGLE) Reports New Positive Data for Pegzilarginase
Aeglea (AGLE) reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.
- GlobeNewswire•2 months ago
Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today presented new positive Phase 1/2 data for pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D) at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders (SIMD) in Bellevue, Washington. The oral presentation was delivered by Dr. George Diaz, M.D., Ph.D., Division Chief of Medical Genetics in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mt. Sinai, New York, NY, and a Principal Investigator on the pegzilarginase Phase 1/2 trial.
- GlobeNewswire•2 months ago
Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
AUSTIN, Texas, April 01, 2019 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme.
- GlobeNewswire•2 months ago
Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
AUSTIN, Texas, March 28, 2019 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of AGLE earnings conference call or presentation 7-Mar-19 9:30pm GMT
Q4 2018 Aeglea Bio Therapeutics Inc Earnings Call
Motley Fool•3 months agoAeglea BioTherapeutics (AGLE) Q4 2018 Earnings Conference Call Transcript
AGLE earnings call for the period ending December 31, 2018.
- GlobeNewswire•3 months ago
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
On Track to Dose First Patient in Pivotal Phase 3 Trial of Pegzilarginase for ARG1-D in Q2 of 2019 Initiated IND-Enabling Studies for New Pipeline Programs Progress with.
- Simply Wall St.•3 months ago
The Aeglea BioTherapeutics Share Price Is Up 11% And Shareholders Are Holding On
If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right individual stocks, you could makeRead More...
- GlobeNewswire•3 months ago
Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
AUSTIN, Texas, Feb. 28, 2019 -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme.
- American City Business Journals•4 months ago
Aeglea aims to raise $60M for treating rare diseases
Much of the money will be used to develop its lead drug, pegzilarginase, which could be used to treat arginase deficiency, a genetic disorder that causes the amino acid arginine and ammonia to accumulate in the blood.
- GlobeNewswire•4 months ago
Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering
Aeglea BioTherapeutics, Inc., (AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $8.00 per share. In addition, and in lieu of common stock, Aeglea is offering to certain investors pre-funded warrants to purchase up to an aggregate of 3,750,000 shares of common stock at a purchase price of $7.9999 per warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The offering is expected to close on or about February 8, 2019, subject to customary closing conditions. Aeglea has also granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock in connection with the public offering.
- GlobeNewswire•4 months ago
Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it intends to offer and sell, subject to market and other conditions, up to $50.0 million of shares of its common stock in an underwritten public offering. Aeglea expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. J.P. Morgan Securities LLC and Evercore Group L.L.C. are acting as joint book-running managers in the offering. Aeglea intends to use the net proceeds from the offering, together with its existing cash resources, to advance the clinical development of pegzilarginase through its Phase 3 pivotal and extension trials in Arginase 1 Deficiency and an ongoing combination trial in cancer, and the remainder to fund continued investigational new drug (IND) enabling activities of multiple pipeline programs, research and development, manufacturing, initial commercialization infrastructure and for working capital and general corporate purposes.
- Simply Wall St.•4 months ago
How Much Of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Do Institutions Own?
Every investor in Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares Read More...
- American City Business Journals•5 months ago
Austin's top-performing stocks of 2018
It's been a wild ride on Wall Street this year but a few Austin companies found a way to buck the general downward trend of the stock market.
- Insider Monkey•5 months ago
Is Aeglea BioTherapeutics, Inc. (AGLE) A Good Stock To Buy?
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren’t very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]
- Simply Wall St.•5 months ago
What Investors Should Know About Aeglea BioTherapeutics, Inc.’s (NASDAQ:AGLE) Financial Strength
The direct benefit for Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
- GlobeNewswire•5 months ago
Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the design of its global pivotal Phase 3 PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) trial to evaluate the safety and efficacy of pegzilarginase, the Company’s lead investigational therapy, in patients with Arginase 1 Deficiency (ARG1-D). The Company has aligned the trial design and endpoints with input from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and plans to conduct a single, global pivotal trial to support registration. PEACE is a global, randomized, double-blind trial designed to assess the effects of treatment with pegzilarginase versus placebo over 24 weeks with a primary endpoint of statistically significant plasma arginine reduction from baseline.
- GlobeNewswire•6 months ago
Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference
AUSTIN, Texas, Dec. 06, 2018 -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme.
- GlobeNewswire•6 months ago
Aeglea BioTherapeutics to Present at Evercore ISI HealthconX Conference
AUSTIN, Texas, Nov. 20, 2018 -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme.
- GlobeNewswire•6 months ago
Report: Exploring Fundamental Drivers Behind Aeglea BioTherapeutics, Barnes & Noble Education, GSI Technology, Morgan Stanley, FTS International, and Crown Crafts — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
